In survival analyses, none of the clinicopathologic features (extent of DCIS, nuclear grade, comedo-type necrosis, HR status, HER2 status, Ki-67 index, p53 overexpression, and margin status) and therapies (type of surgery, adjuvant radiation therapy, and adjuvant endocrine therapy) was associated with ipsilateral breast recurrence. Here, TP53 is linked to ductal breast carcinoma in situ.